CLDN4 and ovarian carcinoma: These results are consistent with previous reports from us as well as others, showing high expression of claudin-3 and claudin-4 in ovarian carcinomas by gene expression profiling [3-13], and confirm high expression of the CPE receptor transcripts in chemotherapy-resistant ovarian tumors.